These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pembrolizumab in the treatment of advanced urothelial cancer. Lundgren KT; Farina MS; Bellmunt J Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016 [TBL] [Abstract][Full Text] [Related]
3. Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma. Zhang N; Wei L; Ye M; Kang C; You H Front Immunol; 2020; 11():592612. PubMed ID: 33329578 [TBL] [Abstract][Full Text] [Related]
4. Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go. Barroso-Sousa R; Tolaney SM Curr Treat Options Oncol; 2020 Jun; 21(7):59. PubMed ID: 32556894 [TBL] [Abstract][Full Text] [Related]
6. Role of Targeted Therapies in Management of Metastatic Urothelial Cancer in the Era of Immunotherapy. Grivas P; Yu EY Curr Treat Options Oncol; 2019 Jun; 20(8):67. PubMed ID: 31254108 [TBL] [Abstract][Full Text] [Related]
7. The future of combination treatment with checkpoint inhibitors in melanoma. Sullivan RJ Clin Adv Hematol Oncol; 2019 Feb; 17(2):96-99. PubMed ID: 30845111 [No Abstract] [Full Text] [Related]
9. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review. Lavoie JM; Black PC; Eigl BJ J Urol; 2019 Jul; 202(1):49-56. PubMed ID: 30730407 [TBL] [Abstract][Full Text] [Related]
10. The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series). Sukari A; Kukreja G; Nagasaka M; Shukairy MK; Yoo G; Lin HS; Hotaling J; Kim H Oral Oncol; 2020 Oct; 109():104744. PubMed ID: 32402656 [TBL] [Abstract][Full Text] [Related]
11. Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management. Rebhan K; Laukhtina E; Shariat SF; Gust KM Curr Opin Urol; 2020 May; 30(3):457-466. PubMed ID: 32235284 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. Tripathi A; Plimack ER Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502 [TBL] [Abstract][Full Text] [Related]
13. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322 [TBL] [Abstract][Full Text] [Related]
14. Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations. Dietrich B; Siefker-Radtke AO; Srinivas S; Yu EY Am Soc Clin Oncol Educ Book; 2018 May; 38():342-353. PubMed ID: 30231356 [TBL] [Abstract][Full Text] [Related]
15. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now? Fazio N; Abdel-Rahman O Curr Treat Options Oncol; 2021 Feb; 22(3):19. PubMed ID: 33559013 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy Combinations and Sequences in Urothelial Cancer: Facts and Hopes. Rodriguez-Vida A; Perez-Gracia JL; Bellmunt J Clin Cancer Res; 2018 Dec; 24(24):6115-6124. PubMed ID: 29991503 [TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. Rebuzzi SE; Perrone F; Bersanelli M; Bregni G; Milella M; Buti S Expert Rev Mol Diagn; 2020 Feb; 20(2):169-185. PubMed ID: 31608727 [No Abstract] [Full Text] [Related]
19. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J; Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005 [TBL] [Abstract][Full Text] [Related]